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Abstract: 
 
Cytokines produced by adipose tissue including adiponectin have been associated 
with metabolic abnormalities. Objective: The purpose of this study was to examine the 
relationship of insulin sensitivity measured by euglycemic hyperinsulinemic insulin 
clamp with plasma adiponectin and other adipokines in young adult African Americans. 
Methods: Participants were relatively healthy African Americans. Anthropometric 
measures, blood pressure, an oral glucose tolerance test and an euglygemic 
hyperinsulinemic insulin clamp were performed. Insulin sensitivity measurements were 
adjusted for percentage of fat mass. Plasma concentrations of adiponectin, plasminogen 
activator inhibitor 1 (PAI-1) and interleukin 6 (IL-6) were assayed on plasma from 
fasting blood samples.  Pearson correlation coefficients and multiple regression models 
were fitted to assess the association between glucose sensitivity and cytokines. Results: 
In univariate analysis, there were statistically significant correlations of plasma 
adiponectin level (r = 0.19, P = 0.004), PAI-1 (r=-0.19, P=0.020) and IL-6 (r=-0.24, 
P<0.001) with measures of insulin sensitivity after adjustment for both fat mass and 
insulin clamp concentration. In multivariate analysis, adiponectin (GMR 1.15 P=0.007), 
PAI-1 (GMR 0.998, P=0.021) and BMI (GMR 0.95, P<0.001) were each independently 
associated with insulin sensitivity. For IL-6 there was no significant association with 
insulin sensitivity independent of obesity. Conclusion: This data show a significant and 
independent positive correlation of adiponectin with insulin sensitivity.  The relationship 
of IL-6 with insulin sensitivity appears to be dependent on adiposity.  
Key Words:  adipokines, adiposity, insulin resistance. 
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Introduction: 
Adipose tissue is recognized not only as an energy reserve organ but also as an 
endocrine organ as it produces several cytokines and hormones designated as 
“adipokines”.1,2  Cytokine involved in inflammation that are secreted in adipose tissue 
include plasminogen activator inhibitor type 1 (PAI-1), interleukin 6 (IL-6), tumor 
necrosis factor α (TNF-α), leptin, and resistin.  Adipocytes also produce adiponectin, a 
hormone that has been associated with anti-inflammatory effects. There appears to be a 
close association between inflammation and obesity given the increased levels of pro-
inflammatory cytokines and decreased level of adiponectin observed in obese individuals 
compared with non-obese individuals.3-5  Obesity related inflammation has been 
proposed as a possible mechanism by which obesity increases insulin resistance and leads 
to diabetes.6-8  Some data suggest that the condition of chronic subclinical inflammation 
can also induce endothelial dysfunction in the vascular bed and hypercoagulability, which 
facilitate vascular injury leading to cardiovascular disease.9  The extent to which 
adipokines induce metabolic abnormalities in humans is not fully resolved.9,10  
Adiponectin is the most abundant adipokine and is synthesized exclusively in 
adipose tissue.11  Animal studies have shown that adiponectin plays an important role in 
regulating insulin sensitivity by inhibiting hepatic gluconeogenesis and stimulating fatty 
acid oxidation in liver and skeletal muscle by activating AMP kinase12 and peroxisome 
proliferator–activated receptor alpha.13-15  In addition, adiponectin deficient mice have 
been shown to be insulin resistant16 and administration of exogenous adiponectin 
improved insulin sensitivity.14  Because insulin resistance is considered a pre-diabetic 
state, the insulin sensitizing effects of adiponectin suggests an anti-diabetic biologic role. 
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African Americans have lower adiponectin levels than Caucasians, Hispanics and 
Asians independently of obesity.17,18  In addition to lower plasma adiponectin levels, 
African Americans present similar or higher expression levels of inflammatory markers 
such as CD68, IL-6 and TNF-α in the adipose tissue.19  This unfavorable adipokine 
profile may underlie the heightened risk for diabetes in African Americans. 
The purpose of this study was to examine the relationship of insulin resistance 
with adiponectin and other adipokines in young adult African Americans. We 
hypothesized that insulin resistance in African Americans is associated with lower 
adiponectin level and higher inflammatory cytokines and that the association of cytokines 
with insulin sensitivity is independent of body fat mass.  
 
Methods:  
Study Population 
The study was conducted on African Americans living in urban Philadelphia aged 
28-52 years. Participants in this study were drawn from a cohort of healthy young adult 
African Americans enrolled in a longitudinal study of blood pressure and risks for 
cardiovascular and renal injury who were previously examined between 1994 and 1999. 
Participants were re-enrolled for this project between August 2001 and July 2007.   
Exclusion criteria for enrollment in 1994-1999 included secondary forms of 
hypertension, diabetes type I or type II, renal or cardiac disease, autoimmune disease and 
polycystic ovary syndrome. Individuals who subsequently developed type II diabetes, as 
well as participants found to be diabetic on re-examination, were included in the study. 
The study protocol was approved by the Institutional Review Board of Thomas Jefferson 
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University. Written informed consent was obtained from each participant at re-
enrollment.   
Study Procedures 
 Each participant was examined on two separate visits, 4-8 weeks apart. Clinical 
assessment at both visits consisted of anthropometric measurements (height, weight, 
waist circumference, and skinfold measurements), and blood pressure (BP). Data on 
health status and health related behaviors were obtained by participant self-report.  An 
oral glucose tolerance test (OGTT) was performed on the first visit and a euglycemic 
hyperinsulinemic clamp was performed on the second visit 
Body mass index (BMI) was calculated as weight (kg) divided by height squared 
(m2). BP measurements were obtained on each subject following a 10-minute rest period 
in a seated position using auscultation with a mercury column sphygmomanometer. The 
average of three successive readings of systolic and diastolic pressure was used as the BP 
values of each visit.   
An OGTT was conducted after a 12-hour overnight fast and a fasting blood 
sample was also obtained for plasma glucose and insulin. A residual aliquot of plasma 
from the fasting blood sample on each participant was stored at -80º C.  Following the 
ingestion of 75 g of glucose solution (Glucola; Ames Diagnostics, Elkhart, IN), blood 
samples were obtained at 30, 60 and 120 minutes post-ingestion and assayed for plasma 
glucose and insulin concentrations.  Plasma glucose concentration was analyzed with the 
glucose oxidase technique (YS Model 27; Glucostat, Yellow Springs, OH).  Plasma 
insulin concentration was determined with a solid phase radioimmunoassay (RIA)(Coat-
a-Count; Diagnostic Products Corp, Los Angeles, CA).  Coefficients of variation for 
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intra- and inter-assay variability for glucose and insulin assays were <5%.  A blood 
sample for fasting lipids was obtained during the first visit. Total cholesterol, low density 
lipoprotein (LDL), high density lipoprotein (HDL), and triglycerides were measured 
using the Hitachi 704 standard enzymatic method in the Lipid Laboratory of Thomas 
Jefferson University. 
The euglycemic hyperinsulinemic clamp was carried out as previously 
described.20-22 In brief, all subjects were required to have a 12-hour overnight fast before 
the insulin clamp procedure.  Blood samples were obtained for baseline plasma glucose 
and insulin concentration.  Hyperinsulinemia was established with a primed constant 
infusion of insulin (Eli Lilly, Indianapolis, IN) at a concentration of 1000 mU/ml in 
normal saline according to the method of Rizza et al.22 The primed infusion rate was 
sufficient to achieve steady-state hyperinsulinemia at 80-120 µU/ml above fasting insulin 
levels with the goal of suppressing hepatic glucose production.  Hyperinsulinemia was 
maintained for 120 minutes, during which time plasma glucose concentration was 
maintained at fasting (baseline) level using a variable infusion of 20% dextrose in water 
(Abbott Lab, Abbott Park, IL).  For participants with elevated fasting glucose greater than 
110 mg/dl, baseline glucose was set at 100 mg/dl as target euglycemic level.  The glucose 
infusion rate was adjusted by the negative feedback equation of DeFronzo et al21 
according to plasma glucose sampled every 10 minutes.  The calculated mean value for 
the glucose infusion rate (M in mg/kg per min) during the final 60 minutes of the clamp 
procedure was the measure of insulin-stimulated glucose uptake, or insulin sensitivity.  
Using anthropometric measures, we computed the fat-free mass for each subject using the 
Durnin and Womersley formula,23 and the insulin-stimulated glucose uptake was 
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expressed as M' (mg/Kg of fat-free mass per min). M' was adjusted for the level of 
steady-state hyperinsulinemia in each case by dividing M' by the mean plasma insulin 
concentration (I in µU per ml) during the final 60 minutes of the clamp procedure to 
derive an insulin sensitivity index (M'/I in mg/kg fat-free mass per min/µU per ml x100).  
 Fasting plasma samples that had been stored at -80ºC were used to assay a panel 
of cytokines considered to be biomarkers of inflammation including IL-6, PAI-1, and the 
anti-inflammatory cytokine adiponectin. All assays for the cytokines were performed by 
ELISA in duplicate using commercially available kits. Kits for Adiponectin, and IL-6 
were obtained from R&D Systems (Minneapolis, MN).  The kits for PAI-1 were obtained 
from Aniara (Mason, OH). The coefficient of variation for these assays was consistently 
<10% and most <6%.  
Statistical Analysis:  
Continuous variables considered for analysis of insulin sensitivity included age, 
BMI, adiponectin, IL-6, and PAI-1. Categorical variables included gender and smoking 
status (response to “do you smoke cigarettes? yes or no”). Due to the skewed distribution 
of the M'/I x100 data, M'/I x100 was natural log transformed for statistical analysis as a 
continuous dependent variable. The data for M/I x100, adiponectin, and IL-6 also had 
skewed distributions and were log transformed for analysis.  For each of these variables, 
the geometric mean and the first and third quartiles on the original scale were presented 
as measures of central tendency and dispersion.  
To summarize tabulated data, subjects were stratified as either having normal or 
abnormal glucose tolerance based on their fasting plasma glucose and OGTT results 
according to ADA criteria: 24 normal glucose tolerance was defined as fasting plasma 
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glucose < 100 mg/dL and two hour post OGTT glucose < 140 mg/dL and abnormal 
glucose tolerance was defined as fasting plasma glucose ≥ 100 mg/dL or two hour 
glucose ≥ 140 mg/dL. BMI status was classified as normal weight (BMI < 25 kg/m2), 
overweight (25 ≤ BMI <30 kg/m2), or obese (BMI ≥ 30 kg/m2). T-tests (assuming 
unequal variances) were used to determine if the means of risk factors or cytokines were 
different between the glucose tolerance groups and Fisher’s exact test was used to test for 
independence between categorical variables and abnormal glucose tolerance.    
To investigate unadjusted linear relationships between continuous M, M' or M'/I 
x100 and adipose tissue cytokines, we calculated and tested the significance of Pearson 
correlation coefficients. Associations between insulin sensitivity (M'/I x100) and 
cytokines adjusted for other study variables were evaluated by multiple linear regression 
models on log M'/I x100 as a dependent variable. Model parameters for independent 
variables from these models are presented as geometric mean ratios (GMR) which 
individually represented the independent multiplicative increase in M'/I x100, on its 
untransformed scale, per unit increase of a continuous independent variable (i.e., age, 
BMI, adiponectin, IL-6, or PAI-1) or per categorical indication (i.e., female or smoker). 
There were 80 subjects (34%) missing PAI-1 measurements and thus we analyzed the 
adjusted association between log M'/I x100 and PAI-1 separately from adiponectin and 
IL-6.   
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Results  
The study cohort consisted of 235 participants, who were stratified as normal 
glucose tolerance (NGT, N = 158) and abnormal glucose tolerance (AGT, N = 77). Table 
1 provides the clinical characteristics of study participants.  Mean age of the participants 
was 40 years and there was no significant age difference between the NGT and AGT 
groups.  In the total study sample, 64% were females and 44% were self-identified 
cigarette smokers with no differences by glucose tolerance groups.  Mean BMI values for 
both NGT and AGT groups were in the obese range (BMI ≥30 kg/m2).  However, the 
AGT group had a significantly higher mean BMI value than the NGT group.  Normal 
BMI (<25 kg/m2) was present in 20% of the NGT group compared to 10% in the AGT 
group, but this difference did not reach statistical significance (p=0.054). There were no 
differences in lipid parameters between glucose tolerance groups.  As expected, fasting 
glucose and fasting insulin were significantly higher in the AGT group (p<0.001 for 
both). Mean systolic and diastolic BP values were not significantly different between 
NGT and AGT groups. 
Table 2 provides data on insulin sensitivity, derived from the insulin clamp 
procedure and cytokine data for the two glucose tolerance groups.  Mean glucose infusion 
rate (M) and insulin sensitivity index (M/I x100) with and without adjustment for total 
body fat were significantly lower, indicating greater insulin resistance in the AGT group, 
(p<0.001 for all comparisons). Adiponectin levels were lower in the AGT group but the 
difference was not statistically significant.  Il-6 and PAI-1 levels were significantly 
higher in the AGT group compared to the NGT group (p=0.041 and 0.048 respectively). 
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Correlation coefficients between the clamp measures of insulin sensitivity with 
each of the cytokine parameters in the entire cohort are presented in Table 3. Although 
the mean adiponectin concentration was not significantly different between glucose 
tolerance groups, there were statistically significant correlations of plasma adiponectin 
level with measures of insulin sensitivity (M), r=0.22, P< 0.001.  When M was corrected 
for adiposity and expressed as mg/Kg of fat free mass (M') the correlation coefficient was 
0.25 (P<0.001).  The correlation coefficient remained significant (r = 0.19, P = 0.004) 
when corrected for clamp insulin concentration (M'/Ix100).  There was a significant 
negative correlation of PAI-1 with insulin sensitivity that remained significant following 
correction for clamp insulin concentration (r=-0.19, P=0.020). The correlation of this 
cytokine with insulin sensitivity measures changed minimally after adjustment for body 
fat mass. There was also a significant correlation of IL-6 with insulin sensitivity that 
remained significant after adjusting for clamp insulin concentration and body fat mass 
(r=-0.24, P<0.001).   
We then performed multiple regression analyses to determine if there were 
independent correlations of adiponectin, IL-6 and PAI-1 with insulin sensitivity 
expressed as M'/I x100.  In these regression models, smoking status, gender, age, and 
BMI were also included as independent variables.  Table 4 provides results of the 
regression analysis of adiponectin and IL-6 with results presented as geometric mean 
ratios.  In this model there was a significant independent effect of BMI on insulin 
sensitivity (GMR 0.95, P<0.001).  In addition there was also a significant independent 
effect of adiponectin on insulin sensitivity (GMR 1.15 P=0.007). No significant 
independent effect was detected for IL-6 (GMR 1.02, P=0.769) or the other variables in 
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this model.  Similar analyses were performed to examine PAI-1. For PAI-1, there was a 
significant independent effect for PAI-1 on insulin sensitivity (GMR 0.998, P=0.021), 
despite the reduction in number of subjects with PAI-1 values (N = 155 cases, data not 
shown). These results indicate that adiponectin correlates with insulin sensitivity 
independent of BMI, and that the correlation of IL-6 with insulin sensitivity is dependent 
on or at least highly collinear with BMI.  
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Discussion 
Our data on a young adult African American cohort demonstrate a significant 
positive relationship of plasma adiponectin level with insulin sensitivity quantified by the 
insulin clamp procedure.  Lower insulin sensitivity, or insulin resistance, was associated 
with lower plasma adiponectin level. This relationship remained statistically significant 
when insulin sensitivity measures were corrected for body fat. Additional regression 
models provide further evidence that the relationship of adiponectin with insulin 
sensitivity is independent of BMI. PAI-1 was also found to have a modest but significant 
negative relationship with insulin sensitivity.  Although a significant negative correlation 
of IL-6 with insulin sensitivity was found in unadjusted analyses, multiple regression 
analysis detected no significant independent association of IL-6 with insulin sensitivity, 
indicating that the relationship of IL-6 with insulin sensitivity is dependent on obesity. 
 Adiponectin is thought to have anti-inflammatory and antidiabetic properties in 
humans with recent studies reporting an inverse relationship between plasma adiponectin 
level and insulin resistance,16,25 metabolic syndrome,26 diabetes,17,27 and cardiovascular 
disease.16,28  There is also a consistently observed inverse relationship between 
adiponectin and obesity.  Weyer et al29 investigated the relationship of adiponectin with 
insulin clamp measures of insulin sensitivity in Pima Indians and reported that the low 
plasma adiponectin concentration was more directly related to with insulin resistance 
than to adiposity or glucose intolerance.  These observations in Pima Indians were 
extended by Stefan et al30 who reported, in a prospective study, that low plasma 
adiponectin levels precede a decline in insulin sensitivity.  Subsequent investigations in 
Caucasians also found a significant positive relationship of adiponectin with insulin 
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sensitivity that was independent of body fat.31  In another study, Abbasi et al,32 stratified 
a modest sample of both obese and non-obese subjects according to insulin sensitivity or 
insulin resistance and compared their plasma adiponectin levels. These investigators 
found higher plasma adiponectin levels among insulin sensitive subjects compared to 
those with insulin resistance, suggesting that the primary association of adiponectin was 
with insulin sensitivity rather than obesity.  Our data in this study advance these findings 
to African Americans and demonstrate an independent association of adiponectin with 
insulin sensitivity in terms of insulin mediated glucose uptake. 
Previous reports have described a relationship of low plasma adiponectin and 
insulin resistance in African Americans.33-35   However, these clinical studies have relied 
on calculated estimates of insulin sensitivity such as homeostasis model assessment, 
based on fasting glucose and insulin concentration. The hyperinsulinemic euglycemic 
insulin clamp is a standard procedure to quantify insulin sensitivity in humans.36, 37 
Although the procedure is technically difficult, it represents a direct measure of insulin 
sensitivity by whole body insulin stimulated glucose uptake.38 Our study represents one 
of the largest African American cohort, in which the insulin clamp procedure was used to 
investigate the relationships between adipose-derived cytokines and insulin sensitivity.   
Several studies have investigated the relationship of inflammation and insulin 
resistance.  Hotamisligil et al measured TNF-α protein in subcutaneous adipocytes from 
obese and non-obese women. Compared to non-obese women, obese women had higher 
adipocyte TNF-α and higher plasma insulin, an indirect measure of insulin resistance.7  
Subsequently, several investigators have reported an inverse association between insulin 
sensitivity and cytokines involved in inflammation such as C-reactive protein (CRP), 
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TNF-α and PAI-18,39,40 with some evidence that the cytokine effect was independent of 
BMI. Pscherer et al41 demonstrated improvement in insulin resistance in obese men with 
impaired glucose tolerance following treatment with valsartan.  These investigators also 
demonstrated a parallel decrease in plasma CRP and increase plasma adiponectin 
following treatment with the renin angiotensin system blocker, suggesting an anti-
inflammatory effect of treatment on insulin resistance.  Most reports on the relationship 
of insulin sensitivity with IL-6 have been based on changes in insulin sensitivity and IL-6 
following weight loss.42,43  Vozarova et al44 studied the relationship of IL-6 with insulin 
sensitivity measured by euglycemic insulin clamp in Pima Indians without diabetes. 
Plasma IL-6 levels correlated negatively with insulin sensitivity but the correlation did 
not remained significant once the insulin mediated glucose uptake (M) was adjusted for 
body fat. The results of our study are consistent with these findings which demonstrate 
that the relationship of IL-6 with insulin sensitivity is mediated through fat mass.   
Our study has some limitations.  The results are based on a cross-sectional design 
study and significant correlations do not demonstrate causality. Our study used BMI as a 
surrogate of body adiposity. We did not distinguish body fat distribution or quantify 
visceral fat mass.  It is known that BMI is a measure of excess weight rather than excess 
fat and does not differentiate between increase in fat, muscle or skeletal weight. Because 
of this BMI can be misleading as a body fat indicator especially in the extremes of age 
(children and older people). There is also a racial disparity with African American 
women having lower fat mass than Caucasian women for a same given BMI. 45  Although 
BMI does not reflect body fat distribution, results of previous studies indicate that 
different patterns of fat accumulation do not fully explain the excess prevalence of 
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diabetes among African Americans.46 On the other hand BMI seems to be fairly accurate 
as a predictor of body fat within sex-age groups and distinguish categories of percentage 
body fat.47   
  Plasma adiponectin levels in this study seem to be somewhat higher than 
adiponectin levels measured in more recent studies in our laboratory on African 
American participants.48 Since the samples used in this study were stored for several 
years there is a possibility that some evaporation of the samples could have occurred.  If 
that was the case, we assume the evaporation happened uniformly and even though the 
adiponectin levels are higher than expected the overall results and associations are still 
valid.  
In summary, our data demonstrate that adiponectin is significantly and positively 
associated insulin-stimulated glucose uptake, independent of fat mass. There is a modest 
negative relationship of the adipokine PAI-1 with insulin sensitivity that is independent 
of fat mass. We also demonstrated that the relationship of IL-6 with insulin sensitivity is 
lost following adjustments for BMI indicating that the relationship of IL-6 with insulin 
sensitivity is dependent on adiposity. Further studies are needed to clarify the mechanism 
by which adipokines affect human metabolism independent of obesity.  
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Tables 1.  Clinical Parameters per Glucose Tolerance Group 
 
    All Subjects  Normal GT  Abnormal GT    
Variable  (N = 235)  (N = 158)  (N = 77)  p-value 
Gender Female                         151 (64%)           98 (62%)           53 (69%)          
 0.384* 
BMI Group Normal                       40 (17%)           32 (20%)            8 (10%)          
 0.054* 
                     Overweight          67 (29%)           48 (30%)           19 (25%)                 
                     Obese              128 (54%)           78 (49%)           50 (65%)                 
Age (yrs)                               40.0 (3.5)         39.9 (3.5)         40.1 (3.7)        
 0.636† 
BMI (kg/m2)                             31.8 (7.7)         30.9 (7.5)         33.8 (7.8)        
 0.008† 
BP Systolic (mmHg)                    125.9 (19.3)        124.9 (20.3)        128.1 (16.9)        
 0.193† 
BP Diastolic (mmHg)                    73.4 (12.6)         73.6 (13.6)         73.1 (10.5)        
 0.768† 
Fasting Glucose (mg/dl)                  102.3 (22.3)         97.6 (8.1)        112.1 (35.3)        
 <.001† 
Fasting Insulin (µU/ml)                  10.5 (8.7)          8.8 (6.2)         14.1 (11.5)        
 <.001† 
HDL-cholesterol (mg/dl)                           48.6 (13.3)         49.3 (14.0)         47.2 (11.7)        
 0.236† 
LDL-cholesterol (mg/dl)             118.2 (33.7)        118.9 (35.5)        116.8 (30.0)        
 0.654† 
Triglycerides (mg/dl)                  87.5 (56.1)         83.6 (55.8)         95.1 (56.4)        
 0.144† 
Total Cholesterol (mg/dl)                  182.5 (36.2)        182.9 (37.2)        181.9 (34.5)        
 0.848† 
Categorical variables are presented as frequency (%) and continuous variables as mean (SD) 
GT: Glucose Tolerance, BMI: Body mass index, BP: Blood Pressure 
*
 Fisher’s exact test 
†
 t-test 
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Table 2.  Insulin Sensitivity Measures and Cytokine Values by Glucose Tolerance Group  
 
    All Subjects  Normal GT  Abnormal GT  p-value 
Variable  (N = 235)  (N = 158)  (N = 77)  (t-test) 
M (mg/kg per min)*                5.7 (2.8)          6.4 (2.9)          4.3 (2.1)        <.001 
M' (mg/kg FFM per min)*               8.9 (4.1)          9.9 (4.2)          6.9 (2.9)        <.001 
M/I x100† (mg/Kg per min/µU per mlx100)                         6.8 [4.2, 12.2]    8.3 [5.3, 13.1]    4.6 [3.0, 7.9]   <.001 
M'/I x100† (mg/Kg FFM per min/µU per 
mlx100)                                                      
 10.9 [6.9, 18.0]   13.0 [8.9, 20.3]    7.6 [5.3, 14.2]   <.001 
Adiponectin (µg/ml)†                     9.1 [5.8, 14.6]    9.5 [6.0, 14.6]    8.3 [4.9, 14.2]   0.171 
Interleukin 6 (pg/ml)†                             2.5 [1.6, 3.6]    2.4 [1.6, 3.4]    2.9 [1.7, 4.0]   0.041 
PAI1 (ng/ml)* ‡                        138.3 (72.9)       129.7 (68.4)       155.5 (79.0)        0.048 
*
 Arithmetic means with (SD) presented 
†
 Data natural log transformed:  geometric means with [1st quartile, 3rd quartile] presented 
‡
 N = 155 
GT: Glucose Tolerance 
FFM: Fat Free Mass 
I: steady-state insulin concentration during clamp in µU per mL 
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Table 3.  Correlations Coefficients (r) Between Cytokines and Insulin Sensitivity  
Measurements 
 
   
 r 
(p-value) 
Insulin Sensitivity  Adiponectin*  Interleukin-6*  PAI1 
M (mg/Kg per min) 0.22 -0.23   -0.21   
 
(<.001) (<.001) (0.008) 
M' (mg/Kg FFM per min) 0.25  -0.17  -0.22 
 
(<.001) (0.008)  (0.005)  
M'/I x100 * (mg/Kg FFM per min)/µU per mlx100       0.19  -0.24   -0.19  
 
(0.004) (<.001) (0.020) 
* Data natural log transformed 
FFM: Fat Free Mass 
I: steady-state insulin concentration during clamp in µU per mL 
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Tables 4.  Multiple Regression Model for Insulin Sensitivity 
(M'/I x100) * 
 
 
 
 Geometric 
Mean Ratio 
 
 (95% CL)  
 
 p-value 
Age (yr)                        0.997  (0.976, 1.019)   0.804 
BMI (unit)                        0.95  (0.93, 0.96)     <.001 
Gender (Female)                     1.15  (0.98, 1.36)     0.078 
Smoking                    1.09  (0.94, 1.27)     0.250 
Adiponectin *           1.15  (1.04, 1.27)     0.007 
Interleukin-6 * 1.02  (0.89, 1.17)     0.769 
* Data natural log transformed 
 
 
